At 2:57 pm; Nifty Pharma index, the largest loser among sectoral indices, was down 2% as compared to 0.43% rise in the Nifty 50 index. In past three trading sessions, the pharma index slipped 5.6% against 0.36% rise in the benchmark index.
Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Glenmark Pharmaceuticals and Lupin were down up to 3% on the National Stock Exchange (NSE).
Lupin hit a 52-week low of Rs 1,030 in intra-day trade after the company said the US Food and Drug administration (USFDA) completed the prior approval inspection (PAI) of its Aurangabad manufacturing plant with one 483 observation.
"The observation was procedural in nature and corrected during the inspection itself," Lupin said in a statement.
Dr Reddy’s Laboratories was down 3% to Rs 2,387, extending 9% decline in past two trading sessions, after the company reported disappointing set of numbers in Q1FY18.
The consolidated net profit for the pharmaceutical company more- than-halved to Rs 59 crore in Q1FY18 against Rs 126 crore in the same quarter year ago. Revenue during the quarter under review grew 3% to Rs 3,316 crore from Rs 3,235 crore in year ago quarter.
Analysts on an average had expected profit of Rs 307 crore on revenues of Rs 3,399 crore for the quarter.
“Our first-quarter results have been below expectations. While headwinds in the form of price erosion due to US customer consolidation continue a lower contribution from new product launches in the US and the GST implementation in India also impacted our performance,” Dr Reddy's Co-Chairman and Chief Executive Officer GV Prasad said while announcing Q1 results.
| Company | 26/07/2017 | 28/07/2017 | 29/07/2017 | % chg* | %chg# |
| Cipla | 575.45 | 566.10 | 559.05 | -1.2 | -2.8 |
| Glaxosmi. Pharma | 2491.85 | 2443.15 | 2399.75 | -1.8 | -3.7 |
| Dr Reddy's Labs | 2707.35 | 2464.95 | 2390.00 | -3.0 | -11.7 |
| Lupin | 1123.60 | 1063.90 | 1034.35 | -2.8 | -7.9 |
| Sun Pharma.Inds. | 579.50 | 550.80 | 532.00 | -3.4 | -8.2 |
| Aurobindo Pharma | 747.70 | 723.90 | 718.70 | -0.7 | -3.9 |
| Glenmark Pharma. | 707.70 | 717.45 | 697.10 | -2.8 | -1.5 |
| Cadila Health. | 548.75 | 545.85 | 543.90 | -0.4 | -0.9 |
| Divi's Lab. | 678.80 | 674.30 | 670.40 | -0.6 | -1.2 |
| Nifty Pharma | 10036.8 | 9672.6 | 9480.00 | -2.0 | -5.5 |
| Nifty 50 | 10020.65 | 10014.5 | 10074.65 | 0.6 | 0.5 |
| LTP : Last traded price on NSE in Rs at 03:07 pm. | |||||
| * % change over previous close; # % change over July 26, 2017 | |||||
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)